Cargando…

Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content

Non-alcoholic steatohepatitis (NASH) is characterized by macrovesicular steatosis with ballooning degeneration of hepatocytes, diffused lobular inflammation, and fibrosis. PPAR ligands are promising therapeutic agents in NASH; accordingly, we evaluated the effects of the first clinically available s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sasaki, Yusuke, Asahiyama, Masato, Tanaka, Toshiya, Yamamoto, Shogo, Murakami, Kentaro, Kamiya, Wakana, Matsumura, Yoshihiro, Osawa, Tsuyoshi, Anai, Motonobu, Fruchart, Jean-Charles, Aburatani, Hiroyuki, Sakai, Juro, Kodama, Tatsuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210999/ https://www.ncbi.nlm.nih.gov/pubmed/32385406 http://dx.doi.org/10.1038/s41598-020-64902-8

Ejemplares similares

Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis
por: Murakami, Kentaro, et al.
Publicado: (2022)

Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα) Pemafibrate
por: Sasaki, Yusuke, et al.
Publicado: (2019)

Overexpression of p54(nrb)/NONO induces differential EPHA6 splicing and contributes to castration-resistant prostate cancer growth
por: Yamamoto, Ryuji, et al.
Publicado: (2018)

PPARα activation directly upregulates thrombomodulin in the diabetic retina
por: Shiono, Akira, et al.
Publicado: (2020)

Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?
por: Fruchart, Jean-Charles, et al.
Publicado: (2021)

Loss of Down syndrome critical region-1 leads to cholesterol metabolic dysfunction that exaggerates hypercholesterolemia in ApoE-null background
por: Muramatsu, Masashi, et al.
Publicado: (2021)

PPARβ/δ activation of CD300a controls intestinal immunity
por: Tanaka, Toshiya, et al.
Publicado: (2014)

Association between Pemafibrate Therapy and Triglyceride to HDL-Cholesterol Ratio
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Triglyceride Level and Cardiovascular Risk Reduction Using Pemafibrate Compared with Fibrates
por: Masuda, Daisaku
Publicado: (2023)

Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia
por: Fruchart, Jean-Charles
Publicado: (2017)

Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing different PPAR isoforms
por: Tachibana, Keisuke, et al.
Publicado: (2005)

Long Noncoding RNA JHDM1D-AS1 Promotes Tumor Growth by Regulating Angiogenesis in Response to Nutrient Starvation
por: Kondo, Ayano, et al.
Publicado: (2017)

Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2019)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice
por: Zhang, Zhe, et al.
Publicado: (2022)

Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy
por: Kanno, Kotaro, et al.
Publicado: (2022)

Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate
por: Honda, Akihiro, et al.
Publicado: (2022)

Effect of fenofibrate and selective PPARα modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion
por: Kitamura, Shigeki, et al.
Publicado: (2023)

Elucidation of Molecular Mechanism of a Selective PPARα Modulator, Pemafibrate, through Combinational Approaches of X-ray Crystallography, Thermodynamic Analysis, and First-Principle Calculations
por: Kawasaki, Mayu, et al.
Publicado: (2020)

Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study
por: Komiya, Ichiro, et al.
Publicado: (2021)

Pemafibrate, a PPAR alpha agonist, attenuates neointima formation after vascular injury in mice fed normal chow and a high-fat diet
por: Horikawa, Tsuyoshi, et al.
Publicado: (2020)

A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice
por: Sairyo, Masami, et al.
Publicado: (2018)

The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice
por: Araki, Masaya, et al.
Publicado: (2018)

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2020)

Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52‐week data from the PROVIDE study
por: Araki, Eiichi, et al.
Publicado: (2019)

Downregulation of ERG and FLI1 expression in endothelial cells triggers endothelial-to-mesenchymal transition
por: Nagai, Nao, et al.
Publicado: (2018)

Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis
por: Honda, Yasushi, et al.
Publicado: (2017)

Erratum:A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice
por: Sairyo, Masami, et al.
Publicado: (2018)

A novel selective PPARα modulator, pemafibrate promotes ischemia-induced revascularization through the eNOS-dependent mechanisms
por: Kawanishi, Hiroshi, et al.
Publicado: (2020)

JMJD1A is a signal-sensing scaffold that regulates acute chromatin dynamics via SWI/SNF association for thermogenesis
por: Abe, Yohei, et al.
Publicado: (2015)

Highly Selective PPARα (Peroxisome Proliferator‐Activated Receptor α) Agonist Pemafibrate Inhibits Stent Inflammation and Restenosis Assessed by Multimodality Molecular‐Microstructural Imaging
por: Iwata, Hiroshi, et al.
Publicado: (2021)

Histone demethylase JMJD1A coordinates acute and chronic adaptation to cold stress via thermogenic phospho-switch
por: Abe, Yohei, et al.
Publicado: (2018)

Cross-enhancement of ANGPTL4 transcription by HIF1 alpha and PPAR beta/delta is the result of the conformational proximity of two response elements
por: Inoue, Tsuyoshi, et al.
Publicado: (2014)

Activation of Bmp2-Smad1 Signal and Its Regulation by Coordinated Alteration of H3K27 Trimethylation in Ras-Induced Senescence
por: Kaneda, Atsushi, et al.
Publicado: (2011)

Case report: a potential modulation of coronary atheroma by lowering triglyceride-rich lipoproteins with pemafibrate: insights from serial near-infrared spectroscopy imaging
por: Murata, Yu, et al.
Publicado: (2023)

Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

Plasma Pentraxin3 is a Novel Marker for Nonalcoholic Steatohepatitis (NASH)
por: Yoneda, Masato, et al.
Publicado: (2008)

Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
por: Arai, Hidenori, et al.
Publicado: (2018)

Pemafibrate Pretreatment Attenuates Apoptosis and Autophagy during Hepatic Ischemia-Reperfusion Injury by Modulating JAK2/STAT3β/PPARα Pathway
por: Cheng, Ziqi, et al.
Publicado: (2021)

Effect of Pemafibrate on Serum Creatinine in Patients with Chronic Kidney Disease
por: Imai, Enyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_02muibejgvle989t3ctc5ttpu2